Last reviewed · How we verify
IPI-145, a PI3K Inhibitor
At a glance
| Generic name | IPI-145, a PI3K Inhibitor |
|---|---|
| Sponsor | SecuraBio |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL (PHASE1, PHASE2)
- PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas (PHASE2)
- A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin Lymphoma (PHASE2)
- A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO) (PHASE1, PHASE2)
- Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma (PHASE3)
- A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer (PHASE1, PHASE2)
- A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO) (PHASE3)
- A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IPI-145, a PI3K Inhibitor CI brief — competitive landscape report
- IPI-145, a PI3K Inhibitor updates RSS · CI watch RSS
- SecuraBio portfolio CI